Citations

Clear

959 citation(s) found for "Service, F J".

Impact of intracardiac echocardiography on readmission morbidity and mortality following atrial fibrillation ablation
Deshpande, Saurabh , Sawatari, Hiroyuki , Ahmed, Raheel , Nair, Rakesh Gopinathan, Somers, Virend K., Chahal, C. Anwar A. , Padmanabhan, Deepak , Gopinathannair, Rakesh , Gopinathannair, Rakesh , Khan, Hassan , Padmanabhan, Deepak , Chahal, Choudhary Anwar A , Ahmed, Raheel , Deshpande, Saurabh , Khanji, Mohammed Y , Somers, Virend K.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 21, 2022 | Volume: 33 | Issue: 12 | Pages: 2496-2503

10.1111/jce.15683 | PMID 36128625 Get It

AbstractIntroductionThe use of intracardiac echocardiography (ICE) is beneficial during the ablation of atrial fibrillation (AF). Evidence is conflicting regarding the clinical impact of using ICE on arrhythmia recurrence and mortality.MethodsPatients undergoing catheter ablation of AF during 2010–2017 were identified using the International Classification of Diseases‐9th and 10th Revision‐Clinical Modification (ICD‐9‐CM and ICD‐10‐CM) from the Nationwide Readmissions Database. Propensity matching was used to generate a control group. Patient demographics, Charlson comorbidity indexes, time from discharge to readmission, and the reason of readmission were extracted.ResultsFrom 2010 to 2017, 51 129 patients were included in the analysis out of which ICE was used in 8005 (15.7%) patients. The in‐hospital mortality at readmission was significantly higher in the patients without ICE use (2.9% vs. 1.7%, p = .02). The length of stay (LOS) at readmission was significantly higher in non‐ICE arm (median [interquartile range, IQR]: 3 [2–6] vs. 2 [3–5] days, p < .0001) with similar healthcare‐associated cost (HAC) in both the groups (median [IQR]: US$7507.3 [4057.8–15 474.2] vs. 7339.4 [4024.8–15 191.6], p = .43). Freedom from readmission was 12% higher (hazard ratio [HR] [95% confidence interval, CI]: 0.88 [0.83–0.94], p < .0001) with the use of ICE at 90‐day follow‐up, which was driven by 24% reduction in heart failure (HF) at follow‐up (HR [95% CI]: 0.76 [0.60–0.96], p = .02).ConclusionsICE use during AF ablation procedure reduces readmissions at 90 days by 12%, driven by a 24% decrease in HF‐related admissions. The non‐ICE arm showed a significantly higher LOS which offsets marginally higher HAC in the ICE arm.
Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline
Mao, Jun J. , Ismaila, Nofisat , Bao, Ting , Barton, Debra L. , Ben‐Arye, Eran , Garland, Eric L. , Greenlee, Heather , LeBlanc, Thomas W. , Lee, Richard T. , López, Ana María , Loprinzi, Charles L. , MacLeod, Jodi , Master, Viraj A. , Ramchandran, Kavitha , Walker, Eleanor , Witt, Claudia M. , Barton, Debra , Leblanc, Thomas , Loprinzi, Charles , Lyman, Gary H , MacLeod, Jodi , Wagner, Lynne , Bruner, Deborah , Witt, Claudia M , Bruera, Eduardo , Mao, Jun J , Ramchandran, Kavitha J , Wagner, Lynne I. , Bruner, Deborah Watkins

Mayo Clinic

Journal of Clinical Oncology | September 19, 2022 | Volume: 40 | Issue: 34 | Pages: 3998-4024

10.1200/jco.22.01357 | PMID 36122322 Get It

PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other health care providers on integrative approaches to managing pain in patients with cancer. METHODS The Society for Integrative Oncology and ASCO convened an expert panel of integrative oncology, medical oncology, radiation oncology, surgical oncology, palliative oncology, social sciences, mind-body medicine, nursing, and patient advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included pain intensity, symptom relief, and adverse events. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 227 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Among adult patients, acupuncture should be recommended for aromatase inhibitor–related joint pain. Acupuncture or reflexology or acupressure may be recommended for general cancer pain or musculoskeletal pain. Hypnosis may be recommended to patients who experience procedural pain. Massage may be recommended to patients experiencing pain during palliative or hospice care. These recommendations are based on an intermediate level of evidence, benefit outweighing risk, and with moderate strength of recommendation. The quality of evidence for other mind-body interventions or natural products for pain is either low or inconclusive. There is insufficient or inconclusive evidence to make recommendations for pediatric patients. More research is needed to better characterize the role of integrative medicine interventions in the care of patients with cancer. Additional information is available at https://integrativeonc.org/practice-guidelines/guidelines and www.asco.org/survivorship-guidelines .
Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patie
Lehrer, Eric J. , Ahluwalia, Manmeet S. , Gurewitz, Jason , Bernstein, Kenneth , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Fakhoury, Kareem , Rusthoven, Chad G. , Mathieu, David , Trudel, Claire, Malouff, Timothy D. , Bonney, Phillip A. , Hwang, Lindsay , Zada, Gabriel , Patel, Samir , Deibert, Christopher P., Franzini, Andrea , Attuati, Luca , Prasad, Rahul N. , Raval, Raju R. , Lee, Cheng‐Chia , Green, Sheryl , Sheehan, Jason P. , Mathieu, David , Ahluwalia, Manmeet S , Kondziolka, Douglas , Ruiz-García, Henry , Yu, Cheng‐Ping , Picozzi, Piero , Palmer, Joshua D. , Yang, Huai‐Che , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | September 16, 2022 | Volume: 138 | Issue: 5 | Pages: 1178-1187

10.3171/2022.7.jns22752 | PMID 36115055 Get It

OBJECTIVE Immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS) are commonly utilized in the management of brain metastases. Treatment-related imaging changes (TRICs) are a frequently observed clinical manifestation and are commonly classified as imaging-defined radiation necrosis. However, these findings are not well characterized and may predict a response to SRS and ICIs. The objective of this study was to investigate predictors of TRICs and their impact on patient survival. METHODS This retrospective multicenter cohort study was conducted through the International Radiosurgery Research Foundation. Member institutions submitted de-identified clinical and dosimetric data for patients with non–small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) brain metastases that had been treated with SRS and ICIs. Data were collected from March 2020 to February 2021. Univariable and multivariable Cox and logistic regression analyses were performed. The Kaplan-Meier method was used to evaluate overall survival (OS). The diagnosis-specific graded prognostic assessment was used to guide variable selection. TRICs were determined on the basis of MRI, PET/CT, or MR spectroscopy, and consensus by local clinical providers was required. RESULTS The analysis included 697 patients with 4536 brain metastases across 11 international institutions in 4 countries. The median follow-up after SRS was 13.6 months. The median age was 66 years (IQR 58–73 years), 54.1% of patients were male, and 57.3%, 36.3%, and 6.4% of tumors were NSCLC, melanoma, and RCC, respectively. All patients had undergone single-fraction radiosurgery to a median margin dose of 20 Gy (IQR 18–20 Gy). TRICs were observed in 9.8% of patients. The median OS for all patients was 24.5 months. On univariable analysis, Karnofsky Performance Status (KPS; HR 0.98, p < 0.001), TRICs (HR 0.67, p = 0.03), female sex (HR 0.67, p < 0.001), and prior resection (HR 0.60, p = 0.03) were associated with improved OS. On multivariable analysis, KPS (HR 0.98, p < 0.001) and TRICs (HR 0.66, p = 0.03) were associated with improved OS. A brain volume receiving ≥ 12 Gy of radiation (V12Gy) ≥ 10 cm3 (OR 2.78, p < 0.001), prior whole-brain radiation therapy (OR 3.46, p = 0.006), and RCC histology (OR 3.10, p = 0.01) were associated with an increased probability of developing TRICs. The median OS rates in patients with and without TRICs were 29.0 and 23.1 months, respectively (p = 0.03, log-rank test). CONCLUSIONS TRICs following ICI and SRS were associated with a median OS benefit of approximately 6 months in this retrospective multicenter study. Further prospective study and additional stratification are needed to validate these findings and further elucidate the role and etiology of this common clinical scenario.
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio, Michael , Kennedy, Kevin , Putman, Michael , Sirotich, Emily , Sattui, Sebastian E. , Foster, Gary , Harrison, Carly , Larché, Maggie , Levine, Mitchell , Moni, Tarin T , Thabane, Lehana , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Machado, Pedro , Sufka, Paul , Wallace, Zachary S. , Gore‐Massy, Monique , Kodhek, More A, Lalonde, Nadine, Tomasella, Laura-Ann, Wallace, John, Akpabio, Akpabio , Alpizar-Rodriguez, D. , Berenbaum, Françis , Buliņa, Inita , Chock, Eugenia Yupei , Duff, Eimear , Hsieh, Evelyn , Kibbi, Lina El, Liew, David , Lo, Chieh , Nudel, Michal, Singh, Aman Dev , Hausmann, Jonathan S. , Sparks, Jeffrey A. , Putman, Michael S , Sirotich, Emily , Sattui, Sebastian E , Machado, Pedro M , Robinson, Philip C , Akpabio, Akpabio , Alpízar-Rodríguez, Deshiré , Berenbaum, Francis , Chock, Eugenia Yupei , Liew, David Fl , Singh, Jasvinder A , Ugarte-Gil, Manuel F , Hausmann, Jonathan S , Simard, Julia F , Sparks, Jeffrey A , Grainger, Rebecca , Hsieh, Evelyn , Thabane, Lehana , Kennedy, Kevin , Liew, Jean W. , Robinson, Philip C. , Yazdany, Jinoos , Howard, Richard A, Wallace, John, Beesley, Richard P. , Conway, Richard , Duarte‐García, Alí , Gheita, Tamer A. , Graef, Elizabeth R. , Singh, Jasvinder A. , Singh, Namrata , Ugarte‐Gil, Manuel F.

Mayo Clinic

RMD Open | September 14, 2022 | Volume: 8 | Issue: 2 | Pages: e002587

10.1136/rmdopen-2022-002587 | PMID 36104117 Get It

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
Barilà, Gregorio , Grassi, Angela , Cheon, HeeJin , Calabretto, Giulia , Chahal, Jasmanet , Vicenzetto, Cristina , Almeida, Júlia , Shemo, Bryna C. , Muñoz‐García, Noemí , Pastoret, Cédric , Oshimi, Kazuo, Sokol, Lubomir, Ishida, Fumihiro , Lamy, Thierry , Morice, William G. , Loughran, Thomas P. , Teramo, Antonella , Chahal, Jasmanet , Vicenzetto, Cristina , Almeida, Julia , Munoz-Garcia, Noemi , Nakazawa, Hideyuki , Morice, William George , Semenzato, Gianpietro , Shi, Min , Gasparini, Vanessa Rebecca , Órfão, Alberto , Zambello, Renato

Mayo Clinic

Blood | September 12, 2022 | Volume: 141 | Issue: 9 | Pages: 1036-1046

10.1182/blood.2021013489 | PMID 36096473 Get It

Abstract Tγδ large granular lymphocyte leukemia (LGLL) is a rare variant of T-cell LGLL (T-LGLL) that has been less investigated as compared with the more frequent Tαβ LGLL, particularly in terms of frequency of STAT3 and STAT5b mutations. In this study, we characterized the clinical and biological features of 137 patients affected by Tγδ LGLL; data were retrospectively collected from 1997 to 2020 at 8 referral centers. Neutropenia and anemia were the most relevant clinical features, being present in 54.2% and 49.6% of cases, respectively, including severe neutropenia and anemia in ∼20% of cases each. Among the various treatments, cyclosporine A was shown to provide the best response rates. DNA samples of 97 and 94 cases were available for STAT3 and STAT5b mutation analysis, with 38.1% and 4.2% of cases being mutated, respectively. Clinical and biological features of our series of Tγδ cases were also compared with a recently published Tαβ cohort including 129 cases. Though no differences in STAT3 and STAT5b mutational frequency were found, Tγδ cases more frequently presented with neutropenia (P = .0161), anemia (P &lt; .0001), severe anemia (P = .0065), and thrombocytopenia (P = .0187). Moreover, Vδ2− cases displayed higher frequency of symptomatic disease. Overall, Tγδ cases displayed reduced survival with respect to Tαβ cases (P = .0017). Although there was no difference in STAT3 mutation frequency, our results showed that Tγδ LGLL represents a subset of T-LGLL characterized by more frequent symptoms and reduced survival as compared with Tαβ LGLL.
Surgical treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial
Darsaut, Tim E. , Magro, Elsa, Bojanowski, Michel W., Chaalala, Chiraz , Nico, Lorena , Bacchus, Emma, Klink, Ruby , Sabatier, Jean-François, Januel, Anne-Christine , Pélissou-Guyotat, I., Roche, Pièrre-Hugues , Brunel, Hervé, Proust, F. , Cornu, Philippe, Gaberel, Thomas , Barbier, Charlotte , Corre, Marine Le, Costalat, Vincent , Jecko, Vincent , Barreau, Xavier , Gauvrit, Jean‐Yves , Derrey, Stéphane , Papagiannaki, Chrysanthi , Abdalkader, Mohamad , Viard, Geraldine, Raymond, Jean , _, _, _, _, Chow, Michael M. C., Findlay, J. Max , Lesiuk, Howard , Drake, Brian , Santos, Marlene dos, Seizeur, Romuald, Pradier, Olivier, Ognard, Julien, Aouni, Mourad Cheddad El , Boursier, Romain, Thillays, F. , Roualdes, Vincent , Calvière, Lionel , Gauvrit, J.Y., Lecouillard, Isabelle, Nouhaud, Elodie, Raoult, Hélène , Eugene, François, Paya, Christophe, Ronzière, Thomas , Trystram, D. , Naggara, Olivier, Emery, Évelyne , Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Riva, Roberto, Biondi, Alessandra , Thines, L. , Bougaci, Nassim , Bracard, Serge, Anxionnat, René , Bernier‐Chastagner, Valérie , Civit, Thierry, Penchet, Guillaume, Gimbert, Edouard, Marnat, Gaulthier, Huchet, Aymeri, Herbreteau, Denis , Bibi, Richard, Ifergan, Héloïse , Janot, Kévin, Peyrière, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Troude, Lucas, Boissonneau, Sébastien , Boch, Anne‐Laure , Clarençon, Frédéric , Nouet, Aurélien , Premat, Kévin, Gascou, Gregory, Lefevre, Pierre-Henri, Riquelme, Carlos , Cébula, H. , Ollivier, Irène , Pop, Raoul, Spatola, Giorgio, Chalumeau, Vanessa, Ikka, Léon , Ozanne, Augustin , Caroff, Jildaz, Chabert, Emmanuel , Rouchaud, Aymeric, Caire, François, Ricolfi, F. , Cao, Catherine, Mourier, Klaus-Luc, Thouant, Pierre, Farah, Walid, Carlson, Andrew P. , Silva, Luciana Alves Oliveira, Froio, Nayara de Lima, Mont’Alverne, Francisco J. A., Martins, Jose Luri, Mendes, George Nilton Nunes , Miranda, Rodrigo Rivera, Rouchaud, Aymeric , Rivera, Rodrigo , Ognard, Julien , Shotar, Eimad , Rouchaud, Aymeric , Ognard, Julien , Bojanowski, Michel W. , Iancu, Daniela , Weill, Alain , Roy, Daniel C. , Cognard, Christophe , Eker, Omer , Graillon, Thomas , Beaujeux, Rémy , Aldéa, Sorin , Piotin, Michel , Shotar, Eimad , Corre, Marine Le, Morandi, Xavier , Nguyen, Thanh N. , Tawk, Rabih G. , Huynh, Thien , Gévry, Guylaine , Gentric, Jean‐Christophe , _, _, _, _, Rempel, Jeremy L , O'Kelly, Cian J , Fahed, Robert , Santos, Marlene dos, Nonent, Michel , Timsit, Serge , Desal, Hubert , Blanc, Raphaël , Eugene, François, Bras, Anthony Le , Ferré, Jean‐Christophe , Paya, Christophe, Rodriguez-Régent, Christine , Kerleroux, Basile , Touzé, Emmanuel , Dumot, Chloé , Charbonnier, Guillaume , Gory, Benjamin , Boulouis, Grégoire , Velut, Stéphane , Bibi, Richard , Troude, Lucas , Sourour, Nader Antoine , Lenck, Stéphanie , Premat, Kévin , Corre, Marine Le, Bonafé, Alain , Dargazanli, Cyril , Gascou, Grégory , Lefèvre, Pierre-Henri , Pop, Raoul , Spelle, Laurent , Chalumeau, Vanessa , Gallas, Sophie , Mihalea, Cristian , Mounayer, Charbel , Thouant, Pierre , Silva, Gisele Sampaio , Montalverne, Francisco Jose

Mayo Clinic

Journal of Neurosurgery | September 9, 2022 | Volume: 138 | Issue: 4 | Pages: 891-899

10.3171/2022.7.jns22813 | PMID 36087316 Get It

OBJECTIVE The Treatment of Brain Arteriovenous Malformations Study (TOBAS) is a pragmatic study that includes 2 randomized trials and registries of treated or conservatively managed patients. The authors report the results of the surgical registry. METHODS TOBAS patients are managed according to an algorithm that combines clinical judgment and randomized allocation. For patients considered for curative treatment, clinicians selected from surgery, endovascular therapy, or radiation therapy as the primary curative method, and whether observation was a reasonable alternative. When surgery was selected and observation was deemed unreasonable, the patient was not included in the randomized controlled trial but placed in the surgical registry. The primary outcome of the trial was mRS score > 2 at 10 years (at last follow-up for the current report). Secondary outcomes include angiographic results, perioperative serious adverse events, and permanent treatment-related complications leading to mRS score > 2. RESULTS From June 2014 to May 2021, 1010 patients were recruited at 30 TOBAS centers. Surgery was selected for 229/512 patients (44%) considered for curative treatment; 77 (34%) were included in the surgery versus observation randomized trial and 152 (66%) were placed in the surgical registry. Surgical registry patients had 124/152 (82%) ruptured and 28/152 (18%) unruptured arteriovenous malformations (AVMs), with the majority categorized as low-grade Spetzler-Martin grade I–II AVM (118/152 [78%]). Thirteen patients were excluded, leaving 139 patients for analysis. Embolization was performed prior to surgery in 78/139 (56%) patients. Surgical angiographic cure was obtained in 123/139 all-grade (89%, 95% CI 82%–93%) and 105/110 low-grade (95%, 95% CI 90%–98%) AVM patients. At the mean follow-up of 18.1 months, 16 patients (12%, 95% CI 7%–18%) had reached the primary safety outcome of mRS score > 2, including 11/16 who had a baseline mRS score ≥ 3 due to previous AVM rupture. Serious adverse events occurred in 29 patients (21%, 95% CI 15%–28%). Permanent treatment-related complications leading to mRS score > 2 occurred in 6/139 patients (4%, 95% CI 2%–9%), 5 (83%) of whom had complications due to preoperative embolization. CONCLUSIONS The surgical treatment of brain AVMs in the TOBAS registry was curative in 88% of patients. The participation of more patients, surgeons, and centers in randomized trials is needed to definitively establish the role of surgery in the treatment of unruptured brain AVMs. Clinical trial registration no.: NCT02098252 (ClinicalTrials.gov)
AACC Guidance Document on the Use of Point-of-Care Testing in Fertility and Reproduction
Nichols, James H. , Ali, Mahesheema , Anetor, John I. , Chen, Li Sheng, Chen, Yu , Das, Saswati , Karon, Brad S. , Kary, Heba, Nerenz, Robert D , Rai, Alex J, Shajani-Yi, Zahra, Thakur, Vinita , Wang, Sihe , Yu, Hoi Ying Elsie, Zamora, Lindsey E , Das, Saswati , Nichols, James H , Collins, Sean P. , Devaraj, Sridevi , Fu, Lei , Rai, Alex J

Mayo Clinic

The Journal of Applied Laboratory Medicine | September 1, 2022 | Volume: 7 | Issue: 5 | Pages: 1202-1236

10.1093/jalm/jfac042 | PMID 36047824 Get It

Abstract Background The AACC Academy revised the reproductive testing section of the Laboratory Medicine Practice Guidelines: Evidence-Based Practice for Point-of-Care Testing (POCT) published in 2007. Methods A panel of Academy members with expertise in POCT and laboratory medicine was formed to develop guidance for the use of POCT in reproductive health, specifically ovulation, pregnancy, premature rupture of membranes (PROM), and high-risk deliveries. The committee was supplemented with clinicians having Emergency Medicine and Obstetrics/Gynecology training. Results Key recommendations include the following. First, urine luteinizing hormone (LH) tests are accurate and reliable predictors of ovulation. Studies have shown that the use of ovulation predicting kits may improve the likelihood of conception among healthy fertile women seeking pregnancy. Urinary LH point-of-care testing demonstrates a comparable performance among other ovulation monitoring methods for timing intrauterine insemination and confirming sufficient ovulation induction before oocyte retrieval during in vitro fertilization. Second, pregnancy POCT should be considered in clinical situations where rapid diagnosis of pregnancy is needed for treatment decisions, and laboratory analysis cannot meet the required turnaround time. Third, PROM testing using commercial kits alone is not recommended without clinical signs of rupture of membranes, such as leakage of amniotic fluid from the cervical opening. Finally, fetal scalp lactate is used more than fetal scalp pH for fetal acidosis due to higher success rate and low volume of sample required. Conclusions This revision of the AACC Academy POCT guidelines provides recommendations for best practice use of POCT in fertility and reproduction.
Genomic profiling for clinical decision making in lymphoid neoplasms
Leval, Laurence de , Alizadeh, Ash A. , Bergsagel, P. Leif , Campo, Elı́as , Davies, Andrew , Doǧan, Ahmet , Fitzgibbon, Jude , Horwitz, Steven M. , Melnick, Ari , Morice, William G. , Nadel, Bertrand , Rosenquist, Richard , Rossi, Davide , Advani, Ranjana H. , Allen, Carl E. , Ansell, Stephen M. , Chan, Wing C. , Cook, James R. , Cook, Lucy , d’Amore, Francesco, Dirnhofer, Stefan , Dreyling, Martin , Dunleavy, Kieron , Hodson, Daniel J. , Klapper, Wolfram , Kim, Won Seog , King, Rebecca L. , Ko, Young Hyeh , LaCasce, Ann S. , Lenz, Georg , Pasqualucci, Laura , Rosenwald, Andreas , Miguel, Jesús F. San , Staudt, Louis M. , Weigert, Oliver , Wilson, Wyndham H. , Wu, Catherine J. , Bagg, Adam , Dirnhofer, S , Bergsagel, P. Leif , de Leval, Laurence , Melnick, Ari , Morin, Ryan D , Nadel, Bertrand , Pileri, Stefano , Rosenquist, Richard , Salaverria, Itziar , Steidl, Christian , Treon, Steven , Zelenetz, Andrew D , Allen, Carl E , Ansell, Stephen M , Chan, Wing C , Cook, James R , Cook, Lucy B , d'Amore, Francesco , Dreyling, Martin , Dunleavy, Kieron , Feldman, Andrew L , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Gribben, John G. , Hermine, Olivier , Hodson, Daniel J , Hsi, Eric D , Inghirami, Giorgio , Jaffe, Elaine S , Karube, Kennosuke , Kataoka, Keisuke , Klapper, Wolfram , King, Rebecca L , Hyeh, Young , LaCasce, Ann Steward , Lenz, Georg , Piris, Miguel , Pittaluga, Stefania , Pasqualucci, Laura , Quintanilla-Martinez, Leticia , Rodig, Scott J , Rosenwald, Andreas , Salles, Gilles A , San-Miguel, Jesus , Savage, Kerry J , Sehn, Laurie H , Semenzato, Gianpietro , Staudt, Louis M , Swerdlow, Steven H , Tam, Constantine S , Trotman, Judith , Vose, Julie , Weigert, Oliver , Wilson, Wyndham H , Winter, Jane N , Wu, Catherine J , Zinzani, Pier Luigi , Zucca, Emanuele , Bagg, Adam , Scott, David W , Morice, William George , Campo, Elías , Advani, Ranjana H , Dogan, Ahmet , Davies, Andrew , Fitzgibbon, Jude , Horwitz, Steven M , Alizadeh, Ash A , Pileri, Stefano , Salaverría, Itziar , Steidl, Christian , Treon, Steven P. , Zelenetz, Andrew D. , Feldman, Andrew L. , Ghia, Paolo , Hermine, Olivier , Hsi, Eric D. , Inghirami, Giorgio , Jaffe, Elaine S. , Karube, Kennosuke , Martin-Subero, Jose Ignacio , Piris, Miguel Á. , Pittaluga, Stefania , Quintanilla‐Martínez, Leticia , Salles, Gilles , Savage, Kerry J. , Sehn, Laurie H. , Swerdlow, Steven H. , Tam, Constantine S. , Vose, Julie M. , Winter, Jane N. , Zinzani, Pier Luigi , Zucca, Emanuele , Scott, David W.

Mayo Clinic

Blood | August 24, 2022 | Volume: 140 | Issue: 21 | Pages: 2193-2227

10.1182/blood.2022015854 | PMID 36001803 Get It

Abstract With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.